FDA approves Poteligeo for use in treatment of MF or SS adult patients

non-Hodgkin lymphomais a cancer caused by lymphocytic cancerMF and SS are non-Hodgkin's lymphoma types of cancerous lymphocytes that affect the skintoday,FDA(announced the approval of Potamulizumab-kpkc) to treat adult patients with mycosis fugoides or Sezari syndrome (Sezary syndrome, SS) who have received at least one systemic therapy for recurrent or refractory stolicomy fungal diseases (mycosfugoides, MF)MogamulizumabMogamumulizumab is a monoclonal antibody developed by kyowa Hakko Kirin(developed humanized CC-toward sedative factor receptor 4 (CCmikon receptor 4, CCR4)CCR4 is a protein expressed on some blood cancerous white blood cells, including skin T-cell lymphomathe company's original POTELLIGENT technology reduces the composition of fucose in the sugar chain structure of this antibody, thereby enhancing cytotoxicity by antibody vectorsThe FDA has granted it the qualification for breakthrough therapy recognition and priority reviewthis approval is based on an open label called MAVORIC, multicenter, randomized clinical phase 3trial(results)In this clinical Phase 3 trial, a total of 372 MF and SS patients were treated with mogamulizumab or vorinostatVolino is an existing chemotherapy for recurrent or refractory skin T-cell lymphoma results showed that patients treated with mogamulizumab had significantly longer progression-free survival (PFS) than patients treated with voolizumab The average PFS in the Mogamulizumab group is 7.6 months, while the average PFS in the Volino group is 3.1 months (p.001) The total remission rates for Mogamulizumab and Volino are 28% and 5% respectively (p0.001 ).